Clinical trials: Vascular Health
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Blood Sugar, Endothelial Function
Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements
To purpose of this study is to assess the effectiveness, safety and tolerability of PEAK ATP® with GlycoCarn®, PEAK ATP® and GlycoCarn® on levels of blood sugar and endothelial function improvement which may lead to improved…
- Trial name
- NCT01855373
- Testing
- PEAK ATP® with GlycoCarn®, PEAK ATP®, GlycoCarn®
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Supplement Formulators, Inc.
Hypertension
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers
The purpose of this study is to evaluate the comparative bioavailability of two fixed dose combination tablet formulations of amlodipine and losartan in healthy volunteers.
- Trial name
- NCT01648231
- Testing
- Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state, Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state, Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
- Where
- Australia
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
Acute Coronary Syndrome
Evaluation of Compliance With Management of Acute Coronary Syndrome on Discharge From Cardiac Intensive Care
To study compliance with secondary prevention during the first months following discharge from the cardiac intensive care unit (CIC) of patients experiencing a first episode of acute coronary syndrome : quantitative compliance…
- Trial name
- SCAVANCE (NCT01105325)
- Where
- 49 sites in France
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Stroke, Engagement, Patient
Gamification of Neurorehabilitation-centric Hand Exercises Post Stroke or Brain Injury
Stroke is the leading cause of adult disability worldwide. Often, severe neurological deficits occur after a stroke and roughly 70% of all stroke survivors have some form of hand function disability.
- Trial name
- NCT05547217
- Testing
- Hand Therapy using the MyHand System
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- IRegained Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Vascular Access Port, Patient Satisfaction
Post-market Clinical Follow-up of Pfmmedical Ports
Prospective, monocentric, non-randomised, observational post-market clinical follow-up study in Germany to obtain post-market information on the pfmmedical ports with a follow-up (FU) of 6 months.
- Trial name
- NCT05209828
- Testing
- pfmmedical implantable vascular access ports
- Where
- Germany
- Volunteers
- 149 people
- Sponsor
- pfm medical gmbh
Diabetic Foot Ulcers
Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers
The primary goal of the study is to demonstrate the increased rate of complete wound closure by AMNIOEXCEL® compared to routine care in patients with chronic diabetic foot ulcers
- Trial name
- NCT02209051
- Testing
- AMNIOEXCEL, Standard of Care, Diabetic Foot Ulcers
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Integra LifeSciences Corporation
Hypertension
Effectiveness of a Digital Health Application for Primary Hypertension (Liebria)
This clinical trial with 328 patients with primary hypertension aims to investigate the effectiveness of the self-guided digital application liebria for patients with primary hypertension.
- Trial name
- NCT06243978
- Testing
- liebria, information brochure on hypertension
- Where
- Germany
- Volunteers
- 328 people
- Sponsor
- Gaia AG
Diabetic Macular Oedema
Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
In this study, the investigators aim to use light masks (Noctura 400) to test the hypothesis that preventing the dark adaptation and associated hypoxia of the rods in the eye could in turn prevent or halt the progression of…
- Trial name
- CANDLE (NCT02207712)
- Testing
- Noctura 400 Eye Mask, Ranibizumab
- Where
- 18 sites in United Kingdom
- Volunteers
- 252 people
- Sponsor
- PolyPhotonix Medical
Resistant Hypertension
JX09 SAD/MAD in Healthy Participants
This is a phase 1, randomized, double-blind, placebo-controlled, multi-part, single and multiple ascending dose study in healthy adult to test the safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of JX09…
- Trial name
- NCT06183671
- Testing
- JX09
- Where
- Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Ji Xing Pharmaceuticals Australia Pty Ltd
Peripheral Artery Disease
SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
- Trial name
- SUCCESS PTA (NCT04776434)
- Testing
- SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
- Where
- 27 sites in Argentina, Germany and 6 more
- Volunteers
- 723 people
- Sponsor
- M.A. Med Alliance S.A.
Hypertension
To Assess Adherence to the Treatment and Quality of Life in Patients With Hypertension
The main goal of this study is to achieve a deeper knowledge of the adherence to antihypertensive drug treatment and to evaluate the quality of life in this population.
- Trial name
- ADHERENCE (NCT00944489)
- Where
- Argentina
- Volunteers
- 1,150 people
- Sponsor
- AstraZeneca
Obesity, Overweight
A Study Investigating the Effects of Neprinol Study Product on Vascular Function
This open-label study investigated the effectiveness of Neprinol on maintaining healthy cardiovascular health in overweight and obese adults. Subjects took 3 capsules, 3 times per day over a period of 12 weeks.
- Trial name
- NCT02862223
- Testing
- Neoprinol
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Stroke, Relatives
Survey of Lifelong Food and Nutrition Assistance (LIFANA) in Stroke Patients and Caregivers
Many elderly suffer from nutritional problems that can cause (or can be caused by) a number of complications such as weakened immune systems and chronic health conditions (diabetes type 2, high blood pressure, cardiovascular…
- Conditions
- Stroke, Relatives, Diet Modification
- Trial name
- NCT03635476
- Testing
- Qualitative interview study
- Where
- Switzerland
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Cereneo AG
Hypertension, Medication Adherence
Collabree: An Intervention to Improve the Regularity of Medication Intake
This a clinical study to improve medication adherence among patients with hypertension in Switzerland. Adult men and women who suffer from high blood pressure and have been prescribed a therapy consisting of at least 4 tablets…
- Trial name
- NCT04708756
- Testing
- Collabree Mobile Phone Application Medication Adherence Booster (simplified version), Collabree Mobile Phone Application Medication Adherence Booster
- Where
- Switzerland
- Volunteers
- 181 people
- Sponsor
- Collabree AG
Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis
Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System
The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and…
- Conditions
- Venous Embolism of Lower Extremities (Diagnosis), Arterial Embolism and Thrombosis, Acute DVT of Lower Extremity, Chronic DVT of Lower Extremity
- Trial name
- NCT07335341
- Testing
- Liberant Thrombectomy System
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Medtronic Endovascular
Thromboangiitis Obliterans (Buerger's Disease)
A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers
This study is a first-in-human clinical trial of drug ATI-1013, in healthy adult cigarette smokers. The main questions it aims to answer are to learn about the safety of drug ATI-1013, how long drug ATI-1013 remains within the…
- Trial name
- NCT07215923
- Testing
- ATI-1013 (0.2 g), ATI-1013 (0.8 g), ATI-1013 (3.2 g)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Antidote Therapeutics, Inc